Femasys (FEMY) CEO receives 68,244 Series D-1 warrants at $0.58 strike

Rhea-AI Filing Summary

Femasys Inc. Chief Executive Officer Kathy Lee-Sepsick received a grant of Series D-1 warrants as a derivative award. She acquired 68,244 Series D-1 warrants on March 19, 2026, each initially exercisable into one share of common stock at an exercise price of $0.58 per share. The warrants are exercisable at her option, subject to Nasdaq Capital Market limitations and adjustment provisions, and expire on March 19, 2036. The warrants were issued in a private placement as consideration under an Omnibus Amendment and Consent Agreement among the company, Lee-Sepsick and other parties.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lee-Sepsick Kathy

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Series D-1 Warrants	68,244	$0.00	--

Holdings After Transaction: Series D-1 Warrants — 68,244 shares (Direct)

Footnotes (1)

1. Holder may, at its option, exercise the Series D-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.58 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series D-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. The reported securities were issued to the reporting person in a private placement as consideration in connection with that certain Omnibus Amendment and Consent Agreement, dated as of March 19, 2026 by and among the Company, the reporting person and the other parties thereto.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee-Sepsick Kathy

(Last) (First) (Middle)

C/O FEMASYS INC.

3950 JOHNS CREEK COURT, SUITE 100

(Street)

SUWANEE GEORGIA 30024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FEMASYS INC [ FEMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series D-1 Warrants	$0.58(1)	03/19/2026		A		68,244		03/19/2026	03/19/2036	Common stock, par value $0.001 per share	68,244(2)	(3)	68,244	D

Explanation of Responses:

1. Holder may, at its option, exercise the Series D-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.58 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series D-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

2. The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

3. The reported securities were issued to the reporting person in a private placement as consideration in connection with that certain Omnibus Amendment and Consent Agreement, dated as of March 19, 2026 by and among the Company, the reporting person and the other parties thereto.

	/s/ Kathy Lee-Sepsick	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Femasys (FEMY) CEO Kathy Lee-Sepsick receive in this Form 4 filing?

Kathy Lee-Sepsick received a grant of 68,244 Series D-1 warrants. Each warrant is initially exercisable into one share of Femasys common stock, providing potential future equity if she chooses to exercise them under the stated terms.

What is the exercise price and term of the FEMY Series D-1 warrants reported?

The Series D-1 warrants have an initial exercise price of $0.58 per common share and expire on March 19, 2036. The exercise price is subject to standard adjustments for stock splits, dividends, combinations, recapitalizations or similar corporate transactions.

How many Femasys shares underlie the CEO’s Series D-1 warrant grant?

The grant covers 68,244 underlying shares of Femasys common stock. Each warrant is linked to one share, so exercising all the warrants, subject to limitations, would allow acquisition of 68,244 common shares at the exercise price.

Why were the FEMY Series D-1 warrants issued to the CEO?

The reported securities were issued as consideration in a private placement connected to an Omnibus Amendment and Consent Agreement dated March 19, 2026. Parties included Femasys, Kathy Lee-Sepsick and other signatories to that agreement.

Are there any limitations on exercising the Femasys Series D-1 warrants?

Yes. The CEO’s ability to exercise the warrants for common shares is subject to certain limitations under Nasdaq Capital Market rules. These restrictions can affect when and how many warrants may be exercised at any given time.

Is this FEMY Form 4 transaction an open-market buy or sale of stock?

No. The filing shows a grant/award acquisition of derivative securities, not an open-market trade. The CEO received Series D-1 warrants at no cash cost as part of an agreement, rather than buying or selling shares on the open market.